What IperionX's (ASX: IPX) Production Ramp-Up Reveals About Its US Titanium Ambitions

Sonal Goyal

11 November 2026 05:38 PM AEDT

What IperionX's (ASX: IPX) Production Ramp-Up Reveals About Its US Titanium Ambitions

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

September-quarter titanium powder production reached 8.7 tonnes.
The company is developing US titanium Manufacturing capabilities.
US government support contributes to its expansion plans.
Commercial-scale production and customer qualification remain important.

IperionX Limited (ASX:IPX) operates in its established Business markets. On 29 October 2026, the company reported its September-quarter titanium production and manufacturing progress.

US Titanium Manufacturing Operations

IperionX aims to produce low-carbon titanium metal and components in the US. Its core technology, known as HAMR, converts titanium scrap and other feedstocks into titanium powder using a process the company says requires less energy than conventional methods.

The company's main asset is its Titanium Manufacturing Campus in Virginia. It also holds the Titan critical minerals project in Tennessee, which contains titanium and rare earth minerals and could, in time, provide domestic feedstock.

IperionX produced 8.7 tonnes of titanium powder in the September 2026 quarter, up from 1.4 tonnes in the June quarter. It ended the period with 19 tonnes of finished powder in inventory and 207 tonnes of titanium scrap feedstock.

September-Quarter Production Progress

The company said it had validated HAMR furnace capacity above its target annualised run rate of 200 tonnes per year, and that powder had consistently met or exceeded Grade 5 titanium specifications.

Downstream, the company commissioned the first of two additional sintering furnaces, with the second scheduled for the December quarter. It also produced 1,500 titanium fasteners during the period.

Defence remains the anchor market. IperionX reported a follow-on purchase order from the US Army's Ground Vehicle Systems Center for titanium fasteners used in Joint Light Tactical Vehicles and trailers.

Government Support and Financial Position

These orders are important as qualification steps, but the Quarterly Report did not disclose a Revenue figure. Investors should view them as evidence of technical progress rather than proof of commercial scale.

Very. IperionX has received a series of US government awards. These include a US$47.1 million award under the Department of Defense's Industrial Base Analysis and Sustainment (IBAS) programme and a US$12.7 million Defense Production Act Title III award, both supporting a planned expansion to 1,400 tonnes a year of capacity.

During the quarter, IperionX secured an US$18.5 million task order under a US$99 million Small Business Innovation Research Phase III contract. It said about US$79.2 million remained under that contract ceiling after the first two task orders.

Commercialisation Risks and Milestones

IperionX reported cash of US$63.0 million at 30 September 2026, up from US$35.2 million at 30 June, after a US public offering in July that raised about US$46.1 million net. It also reported about US$33.7 million of obligated, reimbursable government funding, giving total available Liquidity of roughly US$96.7 million.

Net operating cash outflow for the quarter was US$12.6 million. At that pace, the company has a funding runway, but its expansion plans and the potential development of Titan would require substantially more Capital over time.

IperionX completed a definitive feasibility study on Titan in June 2026. The company reported an after-tax net present value of US$813 million at an 8% discount rate and an after-tax internal rate of return of 39.4%. These are study estimates based on assumptions about prices, costs and approvals, not reported results.

What are the risks?

IperionX has also proposed redomiciling to a Texas-incorporated Parent Company with Nasdaq-listed common stock, subject to shareholder, court and regulatory approvals. The structure and timing of that process may affect how the company is held and traded by Australian investors.

Near-term milestones include commissioning the second sintering furnace, integrating the full GenX line, converting prototype orders into larger production contracts and progressing the 1,400-tonne expansion. Developments on the Atlas-Titan assessment and the redomiciliation proposal will also be important.

Key Insights

IperionX Limited (ASX:IPX) faces a period in which operational delivery and reported financial performance will be important measures of progress. The company’s stated targets should be distinguished from completed results, while the risks identified above remain relevant to execution.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.